ClinicalTrials.gg
Not yet recruitingNCT06697262TELEDOMUpdated Oct 23, 2026

Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia

An interventional study of Remote temperature monitoring device and Home temperature monitoring by a nurse in Oncopediatrics and Febrile Neutropenia, sponsored by Centre Hospitalier Universitaire de la Réunion. Not yet recruiting. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre Hospitalier Universitaire de la Réunion · Not applicable, Interventional, and Prevention

How we know

Updated Oct 23, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
0 Years to 17 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by the visit of an IDE at home (in association with the usual educational sessions), to children at risk of febrile neutropenia, from families with psycho-social vulnerabilities.

The main questions it aims to answer are:

  • Will participants adhere to the telemonitoring system?
  • Is the intervention feasible, in terms of the device's failure to record temperature data?
  • Will parents behave appropriately when using the device?
  • How satisfied will parents and caregivers be?
  • What will be the physical tolerance of the device?
  • On an exploratory basis, will the remote monitoring system be effective for months?

Researchers will compare :

  • patients using the telemonitoring device for continuous temperature monitoring at home, in combination with education sessions on temperature monitoring and the device
  • with patient with temperature monitoring at home by a nurse, 2 times a day, in combination with education sessions on temperature monitoring (without the telemonitoring device at home)
02

Conditions studied

  • Oncopediatrics
  • Febrile Neutropenia

Browse trials for

03

In context

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

This study's planned enrollment of 30 is below the median of 120 across 95 interventional studies indexed under Febrile Neutropenia.

Browse Febrile Neutropenia studies →

Lead sponsor

Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 141 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

patient

  • Aged 0 to 17 inclusive
  • Followed in the Pediatric Onco-Hematology Department
  • Primo-diagnosed with solid or hematological cancer (incident case)
  • Having received a first cycle of chemotherapy
  • Whose family has psycho-social vulnerabilities assessed by the Froger et al. tool, indicating a need for an IDE to support the family in monitoring the patient.

Exclusion criteria

Exclusion Criteria:

Patient:

  • with a dermatosis contraindicating the use of the device
  • Refusing to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    remote temperature monitoring device

    Device: Remote temperature monitoring device

  • Active comparator
    home temperature monitoring by a nurse

    Diagnostic Test: Home temperature monitoring by a nurse

Interventions

  • DeviceRemote temperature monitoring device

    * Use of the Tucky® remote monitoring device for continuous temperature monitoring at home, * In combination with education sessions on temperature monitoring and the device.

  • Diagnostic testHome temperature monitoring by a nurse

    * Home temperature monitoring by a nyrse, twice a day, * In association with education sessions on temperature monitoring.

06

What researchers measure

Primary outcomes

  1. study acceptability rate

    number of patients included/number of eligible patients offered the study.

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 16 interventional studies with no phase under Febrile Neutropenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start May 2026 → Dec 2026, primary completion May 2028 → Dec 2028 and completion May 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartEst.
Dec 2026was May 2026
Primary completionEst.
Dec 2028was May 2028
CompletionEst.
Dec 2028was May 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2026→Dec 2026
Oct 23, 2026
Primary completion
May 4, 2028→Dec 2028
Oct 23, 2026
Study completion
May 4, 2028→Dec 2028
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date May 1, 2026→Dec 2026
    Primary completion May 4, 2028→Dec 2028
    Study completion May 4, 2028→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06697262
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Véronique ARMAND
Contact
ide.coord.oncoped.fguyon@chu-reunion.fr
+262 2 62 90 61 10

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion